Okur Sibel Çağlar, Erdoğan Sinan, Demir Cansu Subaşı, Günel Gülşen, Karaöz Erdal
Department of Physical Therapy and Rehab, Health Science University, Bakirköy Dr Sadi Konuk Training and Research Hospital, İstanbul, Turkey.
Department of Histology and Embryology, İstinye University, Faculty of Medicine, İstanbul, Turkey.
Int J Stem Cells. 2018 May 30;11(1):141-147. doi: 10.15283/ijsc17077.
Cerebral Palsy (CP) is the most common motor disability reason of childhood that occurs secondarily to non-progressive damage in the brain whose development is still ongoing.
6-year-old dystonic-spastic male CP patient received allogenic mesenchymal stem cells treatment four times as 1×10⁶/kg in intrathecal and intravenous administration of Umbilical Cord-derived mesenchymal stem cells (UC-MSCs) ways. Before and after the treatment, the patient was followed-up with FIM (Functional Independent Measurement), GMFCS (Gross Motor Function Classification System 88), Tardieu Scale, TCMS (Trunk Control Measurement Scale), MACS (Manual Ability Classification Scale), CFSS (Communication Function Classification System) for 18 months and received intensive rehabilitation.
Improvements were observed especially in functional scales except for the Tardieu Scale, and no adverse effects were detected aside from a slight pain in the back.
Wider future case studies on UC-MSCs will enable us to assess the efficacy of UC-MSCs which have positive impacts especially on functional scales.
脑性瘫痪（CP）是儿童期最常见的运动残疾原因，继发于大脑仍在发育过程中的非进行性损伤。
一名6岁的肌张力障碍-痉挛型男性CP患者接受了4次同种异体间充质干细胞治疗，采用鞘内和静脉注射脐带间充质干细胞（UC-MSCs）的方式，剂量为1×10⁶/kg。治疗前后，对患者进行了18个月的随访，采用FIM（功能独立性测量）、GMFCS（粗大运动功能分类系统88）、塔迪厄量表、TCMS（躯干控制测量量表）、MACS（手动能力分类量表）、CFSS（沟通功能分类系统），并接受强化康复治疗。
除塔迪厄量表外，在功能量表方面尤其观察到改善，除背部轻微疼痛外未检测到不良反应。
未来对UC-MSCs进行更广泛的病例研究将使我们能够评估UC-MSCs的疗效，其对功能量表尤其具有积极影响。
